Imunon secures USD 10 million structured financing with preferred stock, promissory notes

Imunon, Inc.

Imunon, Inc.

IMNN

0.00
  • Imunon entered definitive agreements for USD 10 million gross proceeds via USD 2.5 million preferred stock issuance and USD 7.72 million in secured promissory notes.
  • Notes total USD 7.72 million across two tranches of USD 2.72 million at 8% interest and USD 5 million at 5% interest.
  • Promissory notes mature 18 months from issuance; interest partly offset by interest earned on bank deposits.
  • Proceeds earmarked to support continued enrollment in the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040800PRIMZONEFULLFEED9731686) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.